/
LUNG
$1.33+$0.08 (+6.40%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$52.8M
42M shares
52-week range
$1.13 – $3.88
7% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.46%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-42.88
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.0M | $32.6M | $32.7M | $48.4M | $53.7M | $68.7M | $83.8M | $90.5M |
| Cost of revenue | $7.7M | $10.2M | $11.5M | $12.8M | $13.8M | $17.9M | $21.8M | $23.4M |
| Gross profit | $12.3M | $22.4M | $21.2M | $35.6M | $39.9M | $50.8M | $62.0M | $67.1M |
| Gross margin | 61.4% | 68.8% | 64.8% | 73.6% | 74.3% | 73.9% | 74.0% | 74.2% |
| R&D | $7.0M | $6.0M | $7.5M | $13.1M | $15.4M | $18.1M | $17.6M | $19.5M |
| Operating income | −$15.1M | −$17.8M | −$32.3M | −$47.3M | −$58.6M | −$61.9M | −$57.7M | −$53.7M |
| EBITDA | −$15.7M | −$16.8M | −$28.4M | −$46.6M | −$56.0M | −$55.1M | −$50.8M | −$49.2M |
| Net income | −$18.5M | −$20.7M | −$32.2M | −$48.7M | −$58.9M | −$60.8M | −$56.4M | −$54.0M |
| Net margin | -92.4% | -63.5% | -98.5% | -100.5% | -109.8% | -88.6% | -67.3% | -59.7% |
| EPS (diluted) | -0.89 | -0.58 | -0.90 | -1.35 | -1.59 | -1.60 | -1.44 | -1.33 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $91M | $-1.14 | $-1.16–$-1.12 | 4 |
| 2027 | $98M | $-1.04 | $-1.10–$-0.98 | 4 |
| 2028 | $110M | $-0.79 | $-1.05–$-0.59 | 4 |
| 2029 | $128M | $-0.41 | $-0.42–$-0.40 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Pulmonx Corporation Common Stock
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
www.pulmonx.com- Employees
- 296
- IPO / List date
- Oct 1, 2020
- HQ
- REDWOOD CITY, CA
Held by traders on TradeandTell
No one on the platform currently holds LUNG.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 320,300 | $413.2K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LUNG yet.
